Bitget App
Trade smarter
Buy cryptoMarketsTradeFuturesEarnAISquareMore
Ark Research Director: Only 0.15% of revenue generated by Robinhood Chain flowed to Ethereum

Ark Research Director: Only 0.15% of revenue generated by Robinhood Chain flowed to Ethereum

Odaily星球日报Odaily星球日报2026/07/14 02:09
Show original

Odaily reported that Lorenzo Valente, Ark’s Director of Cryptocurrency Research, wrote on X stating that Robinhood Chain is the clearest case study for observing how the ETH economic model evolves over time.

Since its inception, Robinhood Chain has generated approximately $816,000 in revenue; Arbitrum, the middleware provider, claimed 10%, about $80,000; then Arbitrum paid settlement fees to the Ethereum mainnet, around $1,538. The profit distribution for this model is roughly as follows — Robinhood: 89%; Arbitrum: 10%; Ethereum: 0.15%.

If your argument is "ETH as currency," then Robinhood building an L2 within the Ethereum ecosystem is highly positive. However, if your argument is "ETH as an income-generating asset," then this is an extremely negative case.

0
0

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.
Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.
Trade now!

You may also like

Saving in the US, paying globally? Industry research warns: Trump’s push to lower drug prices could instead incentivize pharmaceutical companies to raise prices overseas

A study published in The Lancet indicates that Trump's efforts to lower drug prices in the United States may force pharmaceutical companies to raise prices internationally or exit certain markets, potentially leading to a significant reduction in the approximately $11.6 billion saved annually by Medicare.

智通财经2026/09/14 00:46
Saving in the US, paying globally? Industry research warns: Trump’s push to lower drug prices could instead incentivize pharmaceutical companies to raise prices overseas